Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muhammad Khan

Internal Medicine Saginaw, MI Medical Doctor

NPI 1881896975 CMS profile 131357

912 S Washington Ave Ste B, Saginaw, MI 48601

Open in the dashboard

General payments

$6,882

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Muhammad Khan of Saginaw, MI is reported in the CMS Open Payments database as having received $6,882 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,627 63
2024 General $1,472 66
2023 General $1,036 47
2022 General $826 50
2021 General $780 45
2020 General $139 8
2019 General $1,002 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muhammad Khan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Muhammad Khan were reported at $1,627. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Muhammad Khan Internal Medicine median Middle half National median
2019 $1,002 $159 $48–$570 $163
2020 $139 $119 $33–$402 $114
2021 $780 $135 $37–$521 $132
2022 $826 $141 $42–$496 $149
2023 $1,036 $149 $45–$519 $160
2024 $1,472 $154 $47–$537 $164
2025 $1,627 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,436 55 payments
  2. Otsuka America Pharmaceutical, Inc. $641 32 payments
  3. Axsome Therapeutics, Inc. $529 18 payments
  4. Sunovion Pharmaceuticals Inc. $456 29 payments
  5. Janssen Pharmaceuticals, Inc $350 11 payments
  6. Lilly USA, LLC $348 18 payments
  7. Novo Nordisk Inc $341 17 payments
  8. UCB, Inc. $258 13 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $230 14 payments
  10. Novartis Pharmaceuticals Corporation $193 12 payments
  11. Other $2,099 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,860 325 payments
  2. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. BREZTRI $710 22 payments
  2. REXULTI $599 30 payments
  3. Auvelity $529 18 payments
  4. AIRSUPRA $525 12 payments
  5. FARXIGA $446 14 payments
  6. XARELTO $350 11 payments
  7. LOKELMA $303 13 payments
  8. Ozempic $298 15 payments
  9. RYBELSUS $279 14 payments
  10. APTIOM $273 17 payments
  11. Other $3,995 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 318 drugs

Part D claims

37,751

Median for Internal Medicine: 777

Drug cost

$2,714,368

Median for Internal Medicine: $73,373

Branded share of claims

26.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,440 $434,337
Jardiance Empagliflozin Brand 363 $160,122
Ozempic Semaglutide Brand 131 $135,219
Austedo Xr Deutetrabenazine Brand 22 $126,204
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 161 $107,089
Mounjaro Tirzepatide Brand 68 $85,220
Avycaz Ceftazidime/Avibactam Brand 18 $60,972
Trulicity Dulaglutide Brand 70 $58,349
Rexulti Brexpiprazole Brand 56 $49,288
Xarelto Rivaroxaban Brand 116 $47,632

The 10 drugs with the highest cost, of 318 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$212,164

Medicare's payments for the services billed

Medicare patients

668

Average age 77

Services billed

3,295

373 women, 295 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Depression 56%
Ischemic heart disease 52%
Diabetes 51%
Chronic kidney disease 50%
Alzheimer's or dementia 46%
Heart failure 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $214
$214 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $207
$207 71 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $135
  • Lundbeck LLC $20
$155 56 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $79
  • Lilly USA, LLC $11
$90 363 —
Auvelity
  • Axsome Therapeutics, Inc. $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record